

POPULATION

N = 4,744
HFrEF patients

INTERVENTION

Treatment

COMPARATOR

Control

PRIMARY ENDPOINT: CV death or HF worsening

HR 0.74

95% CI: 0.65-0.85

p <0.001

Safety Findings

Limitations

Clinical Implications: SGLT2i should be part of standard HFrEF therapy